Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on SHUTTLE PHARMACTCLS HLDGS stock.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) is a clinical stage pharmaceutical company pioneering innovative therapies aimed at curing cancers. Founded in 2012 by faculty members from Georgetown University Medical Center, Shuttle Pharma focuses on developing radiation sensitizers to enhance the efficacy of radiation therapy (RT). The company’s mission is to improve cancer treatment outcomes, prolong patient survival, and elevate the quality of life for those undergoing therapy.
Shuttle Pharma's flagship product, Ropidoxuridine (IPdR), is a leading candidate designed to be used in combination with RT for treating glioblastoma, a lethal brain tumor currently without a cure. The company has received positive feedback from the U.S. Food and Drug Administration (FDA), including a 'Safe to Proceed' letter, enabling the commencement of Phase II clinical trials. The FDA's guidance has paved the way for Shuttle Pharma to develop Ropidoxuridine further as a radiation sensitizer.
In addition to Ropidoxuridine, Shuttle Pharma is advancing its predictive biomarker program for prostate cancer. This initiative includes licensing intellectual property from Georgetown University to develop diagnostic blood tests. These tests aim to predict the success or failure of RT in prostate cancer patients, thereby informing treatment decisions and improving patient management.
Shuttle Pharma operates with a strong collaborative ethos, partnering with academic institutions and leveraging grant funding from entities like the National Institutes of Health (NIH). The company’s research also extends to histone deacetylase (HDAC) inhibitors, such as its lead HDAC6 inhibitor candidate, SP-2-225, which aims to prevent tumor relapse and enhance antitumor immune responses.
Financially, Shuttle Pharma is actively involved in capital raising initiatives to support its ambitious research and development goals. A recent Rights Offering aims to raise up to $4.5 million, supplementing the company’s resources to advance its clinical trials and diagnostic programs.
Overall, Shuttle Pharmaceuticals Holdings, Inc. is at the forefront of developing groundbreaking therapies that could revolutionize cancer treatment by making radiation therapy more effective and less toxic.
Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) provided a corporate update for Q1 2024. Highlights include FDA and IRB approvals for a Phase 2 clinical trial of Ropidoxuridine for glioblastoma. The company is finalizing site enrollments with 'first patient, first dose' expected in Q2 2024. Shuttle Pharma also created Shuttle Diagnostics to develop diagnostic tests for prostate cancer, and entered exclusive licensing agreements with Georgetown University for predictive biomarkers. The cash balance as of March 31, 2024, was $4.2 million. Recent presentations were made at the Planet MicroCap Showcase and other investor conferences.
FAQ
What is the current stock price of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
What is the market cap of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
What does Shuttle Pharmaceuticals Holdings, Inc. specialize in?
What is Ropidoxuridine?
What is the significance of the FDA's 'Safe to Proceed' letter for Shuttle Pharmaceuticals?
How is Shuttle Pharmaceuticals advancing prostate cancer treatment?
What types of cancer therapies is Shuttle Pharma developing?
What collaboration does Shuttle Pharma have with Georgetown University?
What are the financial strategies of Shuttle Pharmaceuticals?
What is the company's mission?
What other cancers besides glioblastoma is Shuttle Pharma targeting?
How does Shuttle Pharma contribute to the field of cancer research?
